PER Postgame™: Protecting Patients with MS from COVID-19—Exploring the Latest in Prevention and Immunosuppressive Treatment Strategies

Target Audience
This educational activity is directed toward community neurologists, neuroimmunologists, MS specialists, specialty nurse practitioners, physician assistants, registered nurses, pharmacists, and other members of the MS care team.

Activity Overview
The COVID-19 pandemic is an unprecedented health care crisis with disproportionate impact on immunocompromised populations. There are unanswered questions and a lack of understanding about the immune response to SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) treated with disease modifying therapies (DMTs). With a continually changing therapeutic landscape based on emerging evidence, clinicians managing patients with MS require timely education on balancing SARS-CoV-2 infection risk with optimal disease control. This program sheds more light on cell-mediated responses to vaccines, how SARS-CoV-2 vaccines work, and current evidence surrounding DMTs for MS and vaccine response.

The PER Postgame™ is an innovative and unique webcast by PER®. It is an in-depth, engaging data recap program, focusing on novel therapeutic agents and emerging treatment strategies discussed at major medical meetings. This program focuses on abstracts presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.

Learning Objectives
Upon successful completion of this activity, you should be better prepared to:

Describe the immunological pathways activated by vaccine administration
Explain the mechanisms underlying the antiviral efficacy of current SARSCoV-2 vaccines
Discuss the impact of disease-modifying therapies (DMTs) on anti-SARS-CoV-2 vaccine response in patients with MS
Implement timely, evidence-based strategies for addressing COVID-19 in patients with MS